Form 8-K · Current Report · Filed 2024-05-07
Halozyme Reports Q1 2024 Financial Results and Announces New $750M Share Repurchase Program
Halozyme Therapeutics, Inc. reported its Q1 2024 financial results on May 7, 2024, showing a 21% year-over-year increase in revenue to $196 million, net income of $77 million, and adjusted EBITDA of $116 million. The company also announced a new $750 million share repurchase program. Halozyme reiterated its 2024 financial guidance, expecting total revenue between $915 million and $985 million, adjusted EBITDA between $535 million and $585 million, and non-GAAP diluted EPS between $3.55 and $3.90.
- Filer
- Halozyme Therapeutics Inc. HALO · NASDAQ
- Filed
- Accession
- 0001159036-24-000036
- CIK
- 0001159036
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$40.86
Next session
+2.8%
Since filing
+169.8%
Latest close
$110.24
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from HALO reporting the same item, with the next session's move:
Exhibits (1)
About Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.
Never miss another HALO filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.